- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03939039
Recruitment Status Recruiting
First Posted May 6, 2019
Last update posted May 6, 2019
The mechanism of the majority of the dyslipidemia is multifactorial at the molecular level and remains elusive in more than 50% of the patients in many clinical conditions. Next generation sequencing, a booming strategy, improves the molecular diagnosis efficiency in both monogenic and polygenic dyslipidemia. In order to decipher the mechanisms involved in the occurrence of dyslipidemia, in addition to the exploration of known candidate genes and Single Nucleotide Polymorphisms (SNP) involved in polygenic modulation, new genes involved in the regulation of lipoprotein metabolism or associated with lipids concentrations need to be sequenced in large groups of dyslipidemic patients. The goal of this project is to gain new insight into genotype/phenotype correlation.
Deoxyribonucleic Acid (DNA) of patients will sequenced using Sanger and Illumina Next-Generation Sequencing (NGS) methodology combined with PapilLyon, the pipeline developed by the Hospices Civils de Lyon (HCL) bioinformatics team, which allows more than 350 genes potentially involved in plasma lipoprotein metabolism to be explored.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- patients with a family documented history of primary hypercholesterolemia,
hypertriglyceridemia, hypobetalipoproteinemia, combined hypolipidemia and combined
hyperlipidemia according to the European Atherosclerosis Society and/or published
- patients with major secondary dyslipidemia.
- inability to provide written informed consent
- lack of legal representative
Contact: Mathilde Di Filippo 4 72 11 89 94 ext 33 email@example.com
Contact: Oriane Marmontel 4 72 12 97 08 ext 33 firstname.lastname@example.org
Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Département de biochimie et biologie moléculaire Grand Est
Hospices Civils de Lyon
Principal Investigator: Philippe Moulin, PhD Hospices Civils de Lyon